| Literature DB >> 32595968 |
Elise Piraux1,2,3, Gilles Caty1,3,4, Frank Aboubakar Nana2,5, Gregory Reychler2,5.
Abstract
Despite its beneficial effects, radiotherapy still results in a range of side effects that negatively impact quality of life of patients. Exercise has been shown to counteract the side effects induced by cancer treatment. This narrative review aims to provide an up-to-date review of the effects of an exercise intervention in cancer patients during radiotherapy. A literature search was performed on PubMed to identify original articles that evaluated the effects of an exercise programme to alleviate treatment-related side effects in cancer patients undergoing radiotherapy with or without other cancer treatments. Benefits related to exercise training have been shown in breast, prostate, rectal, lung, head and neck cancer patients undergoing radiotherapy. Therefore, exercise should be considered as a concurrent treatment alongside radiotherapy to alleviate treatment-related side effects and facilitate effective recovery. Due to the onset and progress of treatment-related side effects throughout radiotherapy, a regular clinical evaluation seems strongly advisable in order to continuously adapt the exercise programme depending on symptoms and side effects. An exercise professional is needed to personalize exercise training based on the medical condition and tailor it throughout the intervention according to progress and the patient's medical status. Future studies are needed to confirm the potential benefits of exercises observed on treatment-related side effects. Furthermore, because of the narrative design of this study, a systematic review is required to evaluate the strength of the evidence reported.Entities:
Keywords: Cancer; exercise; oncology; radiotherapy; rehabilitation
Year: 2020 PMID: 32595968 PMCID: PMC7301662 DOI: 10.1177/2050312120922657
Source DB: PubMed Journal: SAGE Open Med ISSN: 2050-3121
Figure 1.Vicious cycle of fatigue in cancer patients.
Figure 2.PRISMA flow diagram.
Characteristics of included studies.
| Authors, year | Study design | Sample (n) | Cancer type, RT duration, RT regimen, planned treatment, stage | Setting, supervision | Duration of programme (weeks) | Frequency (x/weeks) | Duration (min per session) | Intervention | Adherence, exercise-related adverse events (n) | Results |
|---|---|---|---|---|---|---|---|---|---|---|
| Drouin et al.,[ | Pilot RCT | n = 21 (0:21) | Breast, 7 weeks | H, nS | 8 | 3–5 | 20–45 | Aerobic (walking, 20–45 min, 50%–70% HRmax) | N/A | ↗ Exercise capacity (IG) after 8 weeks |
| Drouin et al.,[ | Pilot RCT | n = 21 (0:21) | Breast, 7 weeks | H, nS | 8 | 3–5 | 20–45 | Aerobic (walking, 20–45 min, 50%–70% HRmax) | N/A | ↘ Haemoglobin (CG), (CG vs IG) after 8 weeks |
| Hwang et al.,[ | RCT | n = 37 (0:37) | Breast, 5 weeks | I, S | 5 | 3 | 50 | Aerobic (walking and cycling, 50%–70% HRmax) | N/A | ↗ Total QoL score (IG vs CG) after 5 weeks |
| Milecki et al.,[ | RCT | n = 66 (0:66) | Breast, 5 weeks | I, S | 6 | 5 | 40–45 | Aerobic (cycling, 40–45 min, 65%–70% HRmax) | N/A | ↗ Functional exercise capacity (IG) after 6 weeks |
| Yang et al.,[ | Non-RCT | n = 47 (0:47) | Breast, 6 weeks | I, S | 6 | 3 | 50–60 | Aerobic (walking, 20–30 min, 40%–65% HRmax or 10–12 RPE) | N/A | ↘ Total fatigue score (IG) after 6 weeks |
| Steindorf et al.,[ | RCT | n = 155 (0:155) | Breast, 6 weeks | I, S | 12 | 2 | 60 | Resistance (major muscle groups, 3 sets, 8–12 reps, 60%–80% 1-RM) | 79% | ↘ Total fatigue score (IG), (IG vs CG) after 13 weeks |
| Schmidt et al.,[ | RCT | n = 103 (0:103) | Breast, 6 weeks | I, S | 12 | 2 | 60 | Resistance (major muscle groups, 3 sets, 8–12 reps, 60%–80% 1-RM) | N/A | ↗ IL-6 (CG vs IG) after 7 weeks |
| Wiskemann et al.,[ | RCT | n = 146 (0:146) | Breast, 6 weeks | I, S | 12 | 2 | 60 | Resistance (major muscle groups, 3 sets, 8–12 reps, 60%–80% 1-RM) | 83% | ↗ Hip circumference (CG vs IG) after 13 weeks |
| Steindorf et al.,[ | RCT | n = 160 (0:160) | Breast, 6 weeks | I, S | 12 | 2 | 60 | Resistance (major muscle groups, 3 sets, 8–12 reps, 60%–80% 1-RM) | 79% | ↗ Sleep problems (CG vs IG) after 7 and 13 weeks |
| Windsor et al.,[ | RCT | n = 66 (66:0) | Prostate, 4 weeks | H, nS | 4 | 3 | 30 | Aerobic (walking, 30 min, 60%–70% HRmax) | 97% | ↘ Haemoglobin, haematocrit and albumin (IG), (CG) after 4 weeks |
| Kapur et al.,[ | Retrospective study | n = 66 (66:0) | Prostate, 4 weeks | H, nS | 4 | 3 | 30 | Aerobic (walking, 30 min, 60%–70% HRmax) | 97% | ↘ Mean rectal toxicity over the 4 weeks of RT (IG vs CG) |
| Monga et al.,[ | RCT | n = 21 (21:0) | Prostate, 7–8 weeks | I, S | 8 | 3 | 50–55 | Aerobic (walking, 30 min, 65% HRmax) | 82% | ↗ Exercise capacity (IG), (IG vs CG) after 8 weeks |
| Segal et al.,[ | RCT | n = 121 (121:0) | Prostate, N/A | I, S | 24 | 3 | AG: 15–45 | AG: aerobic (walking/cycling/elliptical, 50%–75% VO2peak) | AG: 88%, RG: 83% | ↘ Exercise capacity (CG), (CG vs RG) after 24 weeks |
| Truong et al.,[ | Pilot study | n = 80 (80:0) | Prostate, 6–8 weeks | H, nS | 12 | 3 | ⩾20 | Aerobic (walking, ⩾20 min, 60%–70% HRmax) | 88% | ↗ Total fatigue score (CG) after 8 and 24 weeks after RT |
| Hojan et al.,[ | Pilot RCT | n = 54 (54:0) | Prostate, 8 weeks | I, S | 8 | 5 | 50–55 | Aerobic (walking/running/cycling, 30 min, 65%–70% HRmax) | 95% | ↗ Functional exercise capacity (IG), (IG vs CG) after 8 weeks |
| Heldens et al.,[ | Pilot study | n = 9 (8:1) | Rectal, 5.5 weeks | I, S | 10 | 2 | 45–60 | Aerobic (walking and cycling, 30 min, 50%–60% HRmax the 1st week, 13–14 RPE from the 2nd week) | 96% | Feasibility |
| Morielli et al.,[ | Pilot study phase I | n = 18 (12:6) | Rectal, 5–6 weeks | I, S during NACRT (6 weeks), | 12–14 | 3 | 40 | Aerobic (walking/cycling/rowing/elliptical, 40 min, 40%–60% VO2R) | 74% | Feasibility |
| Singh et al.,[ | Pilot study | n = 10 (5:5) | Rectal, N/A | I, S | 16 | 2 | 60 | Aerobic (walking/running/cycling/rowing, 20 min, 60%–80% HRmax) | 80% | Feasibility |
| Singh et al.,[ | Pilot study | n = 10 (7:3) | Rectal, N/A | I, S | 10 | 2 | 60 | Aerobic (walking/cycling, 20 min, 60%–80% HRmax) | 77% | Feasibility |
| Moug et al.,[ | RCT, Phase 1 | n = 48 (31:17) | Rectal, 5 weeks | H, nS | 13–17 | 3–5 | N/A | Aerobic (walking, 1500–3000 daily steps accumulated above baseline, 100 steps/min) | 75% | Feasibility |
| Rogers et al.,[ | Pilot RCT | n = 15 (12:3) | HNC, 6 weeks | I, S during RT (6 weeks) | 12 | 2 | 60 | Resistance (major muscle groups, 10 reps, light resistance band the first 2 weeks, gradually increased every 2 weeks) | 83% during RT | ↗ Fatigue (CG) after 6 weeks |
| Samuel et al.,[ | RCT | n = 48 (42:6) | HNC, 6 weeks | I, S | 6 | 5 | N/A | Aerobic (walking, 15–20 min, 3–5/10 RPE) | N/A | ↗ Functional exercise capacity (IG), (IG vs CG) after 6 weeks |
| Zhao et al.,[ | Pilot RCT | n = 18 (17:1) | HNC, 7 weeks | I, S during RT (7 weeks) | 14 | 3 | 60 | Aerobic (walking, 30 min, 11–13/20 RPE) | 72% | ↘ Muscle strength (CG vs IG) after 7 and 14 weeks |
| Capozzi et al.,[ | RCT | n = 60 (49:11) | HNC, 6.5 weeks | I, S (2/week) and H, nS (2/week) | 12 | 4 | N/A | Resistance (major muscle groups, 2–3 sets, 8 reps, 8–10 RM) | IDT = 45% | ↗ Recommended PA min/week (IDT after 12 and 24 weeks), (IDT vs IAT after 12 weeks) |
| Sandmael et al.,[ | Pilot RCT | n = 41 (25:16) | HNC, 6 weeks | I, S | IDT = 6 | IDT = 2 | IDT = 30 | Resistance (UL and LL muscle groups, 3–4 sets, 6–12 RM) | IDT = 74% | ↘ LM (IDT), (IAT) after 6 weeks |
| Lonkvist et al.,[ | Pilot study | n = 12 (7:5) | HNC, 6 weeks | I, S | 12 | 3 | N/A | Resistance (major muscle groups, 2–3 sets, 15–8 RM) | 77% | ↔ Functional performance, lower muscle strength after 6 and 13 weeks |
| Grote et al.,[ | Pilot RCT | n = 20 (15:5) | HNC, 7 weeks | I, S | 7 | 3 | 30 | Resistance (major muscle groups, 3 sets, 8–12 reps, ⩾7/10 RPE) | 80% | ↔ Total fatigue score, total cancer-specific QoL score, fat mass, LM after 7 and 15 weeks |
| Samuel et al.,[ | RCT | n = 148 (131:17) | HNC, 7 weeks | I, S during CRT (7 weeks) | 11 | 5 | N/A | Aerobic (walking, 15–20 min, 3–5 RPE) | 75% | ↗ Functional exercise capacity (IG vs CG) |
| Egegaard et al.,[ | Pilot RCT | n = 15 (5:10) | NSCLC, 7 weeks | I, S | 7 | 5 | 20 | Aerobic (cycling, 20 min (5 min warm-up; 5 s × 30 s intervals at 80%–95% of iPPO; 5 min continuous cycling at 80% of iPPO and 5 s × 30s intervals at 80%–95%) | 90% | Feasibility |
ADT: androgen deprivation therapy; AG: aerobic group; ASM: appendicular skeletal muscle; BMI: body mass index; CG: control group; CRT: chemoradiotherapy; CT: chemotherapy; Gy: grey; FM: fat mass; H: home-based; HNC: head and neck cancer; HRmax: maximal heart rate; I: in-hospital; IAT: intervention after treatment; IDT: intervention during treatment; IG: intervention group; IL-1ra: interleukin-1 receptor antagonist; IL-6: interleukin-6; LL: lower limb; LM: lean mass; MIPT: maximal isokinetic peak torque; MVIC: maximal voluntary isometric contraction; N/A: not available; NACRT: neoadjuvant chemoradiotherapy; nS: non-supervised; NSCLC: non-small-cell lung carcinoma; PA: physical activity; PCa: prostate cancer; PSA: prostate-specific antigen; QoL: quality of life; RCT: randomized controlled trial; Reps: repetitions; RG: resistance group; RM: repetition maximum; ROM: range of motion; RPE: rating of perceived exertion; RT: radiotherapy; S: supervised; SD: standard deviation; UL: upper limb; VO2: volume of oxygen consumption; VO2 peak: peak oxygen uptake; VO2R: oxygen uptake reserve.
Same sample and same design intervention as Drouin et al.[37]
Same sample and same design intervention (BEST study).[45]
Same sample and same design intervention as Windsor et al.[60]
↑ Significant increase; ↓ significant decrease; ↔ no significant change/difference.
Figure 3.Side effects and symptoms influencing the tolerance and safety of exercise during radiotherapy.
Source: Adapted from Campbell et al.[29]